Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

303
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
303
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Drug Therapy01:28

Drug Therapy

44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
44
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peri-ictal magnetic resonance imaging findings in pediatric seizures: a scoping review on pearls and pitfalls from a heterogeneous population.

Translational pediatrics·2026
Same author

Exploring the Role of Early Add-On Cenobamate in Uncontrolled Focal Epilepsy: A Critical Appraisal of the Evidence.

Neurology and therapy·2026
Same author

Global Socioeconomic Context and Brain Ageing in Epilepsy: an ENIGMA-Epilepsy study.

medRxiv : the preprint server for health sciences·2026
Same author

Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable intestinal patterning.

Cell·2026
Same author

Neuropsychological assessment in adult epilepsy: rationale, test selection, and clinical integration across non-surgical care in Italian patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Sex-related structural alterations across common epilepsies: a worldwide ENIGMA study.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 4, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K

Conversion to Brivaracetam Monotherapy in Clinical Practice: A Retrospective Study.

Simona Lattanzi1, Nicoletta Foschi2, Chiara Martellino3

  • 1Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy. alfierelattanzisimona@gmail.com.

Neurology and Therapy
|February 1, 2024
PubMed
Summary

Brivaracetam (BRV) monotherapy demonstrated high retention rates (88.6% at 6 months) and seizure freedom (72.7% at 6 months) in adults with focal epilepsy. This real-world study suggests BRV is effective and safe for focal seizure management.

Keywords:
Antiseizure medicationBrivaracetamEpilepsyFocal seizures

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

526
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Related Experiment Videos

Last Updated: Jul 4, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

526
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Practice

Background:

  • Focal epilepsy affects numerous adults, necessitating effective monotherapy options.
  • Real-world data is crucial for understanding treatment effectiveness beyond clinical trials.

Purpose of the Study:

  • To evaluate the real-world effectiveness and safety of brivaracetam (BRV) as conversion monotherapy for adults with focal epilepsy.
  • To assess treatment retention, seizure freedom rates, and adverse events associated with BRV monotherapy.

Main Methods:

  • Retrospective, observational, non-interventional study design.
  • Inclusion of adult patients with focal epilepsy converting to BRV monotherapy.
  • Assessment of primary outcomes: BRV retention rates at 6 and 12 months; secondary outcomes: seizure freedom, adverse events.

Main Results:

  • High BRV monotherapy retention rates: 88.6% at 6 months and 83.9% at 12 months.
  • Significant seizure freedom rates: 72.7% at 6 months and 58.1% at 12 months.
  • Low incidence of adverse events (13.6%), with somnolence being the most common; 4.5% discontinued due to AEs.

Conclusions:

  • Brivaracetam monotherapy shows promise as a valuable treatment option for focal epilepsy in real-world clinical practice.
  • BRV demonstrated favorable effectiveness and safety profiles, particularly for patients switching from levetiracetam.